Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | PNP | P00491 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8667323 | 0.79 | PNP (0.53) | PNP | |
| SCHEMBL8340809 | 0.62 | JAK2 (0.34) | JAK2JAK1PNP | |
| SCHEMBL8326030 | 0.59 | ADORA1 (0.39) | PNP | |
| SCHEMBL3845982 | 0.58 | — | — | |
| SCHEMBL8836044 | 0.55 | METAP2 (0.40) | — | |
| SCHEMBL14321806 | 0.54 | PNP (0.44) | PNP | |
| SCHEMBL912733 | 0.52 | PNP (0.70) | PNP | |
| SCHEMBL2254722 | 0.51 | POLB (0.48) | JAK2 | |
| SCHEMBL65614 | 0.51 | GDA (0.40) | PNP | |
| SCHEMBL10910465 | 0.50 | PNP (0.37) | PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8592397-B2 | Compositions and methods for combination antiviral therapy | GILEAD SCIENCES, INC. (US) | 2013-11-26 | — | — | US | disclosed |
| EP-1828145-A4 | 2' AND 3' - SUBSTITUTED CYCLOBUTYL NUCLEOSIDE ANALOGS FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | UNIV EMORY (US) | 2009-08-19 | — | — | EP | disclosed |
| US-20090143314-A1 | COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY | GILEAD SCIENCES, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| EP-1828145-A2 | 2' AND 3' - SUBSTITUTED CYCLOBUTYL NUCLEOSIDE ANALOGS FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | EMORY UNIVERSITY (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20060246130-A1 | Compositions and methods for combination antiviral therapy | GILEAD SCIENCES, INC. | 2006-11-02 | — | — | US | disclosed |
| WO-2006063281-A2 | 2' AND 3' - SUBSTITUTED CYCLOBUTYL NUCLEOSIDE ANALOGS FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | EMORY UNIVERSITY (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143314-A1 | COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY | DCTD, TYMP, TYMS | JAK2 4629/4885JAK1 3101/4885PNP 11/4885 |
| US-20060246130-A1 | Compositions and methods for combination antiviral therapy | DCTD, TYMP, MTAP | JAK2 4657/4885JAK1 3175/4885PNP 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.